Teva's Allergan Generics Buy Progressing, Though Timeline Might Slip
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries Ltd. assured investors that its $40.5bn deal to buy Allergan PLC's generic drug business is progressing as expected during the company's fourth quarter sales and earnings call on Feb. 11, although CEO-Global Generic Medicines Sigurdur Olafsson said the timeline of the closing could slip from the first quarter into the first part of the second.